Biotech Business - February 23, 2026
Beactica secures EUR 2.5 million from the European Innovation Council
Beactica Therapeutics, together with glioblastoma researchers at KU Leuven, has been awarded the grant to advance a precision immune therapy for glioblastoma.
MedTech Business - February 23, 2026
FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma
The US Food and Drug Administration (FDA) has informed the company that it can proceed with the proposed clinical investigation for FG001.
Agreement - February 23, 2026
Affibody signs Letter of Intent with SHINE Technologies
A Letter of Intent (LOI) has been signed with SHINE Technologies as an additional supplier of non-carrier-added Lutetium-177 (n.c.a. Lu-177).
Biotech Business - February 17, 2026
CubaseBio secures EUR 5.9 million in blended financing
The funding comprises a EUR 2 million non-dilutive grant from the European Innovation Council (EIC) Transition program and EUR 3.9 million in private capital and convertibles from Voima Ventures, Nordic Science Investments (NSI), Illumina Ventures, Almi invest, Life Science Invest and several undisclosed private investors from the genomics technology space.
Digital health - February 16, 2026
Gosta Lab’s AI Operating System registered as medical device in EUDAMED
It is the first AI operating system in Europe to achieve registration in EUDAMED as a medical device, according to the company.
MedTech Business - February 16, 2026
FDA grants De Novo Classification request from Amferia
Amferia's antibacterial wound dressing has been granted approval by the US Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the US market with a unique Class 2 medical device antibacterial dressing for advanced wound care.
